Close up on atomoxetine: a nonstimulant choice for treating ADHD.
Allen
Christopher
C
University of Mississippi School of Pharmacy, Jackson, Miss, USA.
Pitcock
Jay
J
D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D001835:Body Weight; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D002755:Choice Behavior; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004348:Drug Labeling; D006801:Humans; D009730:Nursing Assessment; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011437:Propylamines / Q000494:pharmacology / Q000627:therapeutic use*; D012307:Risk Factors; D013405:Suicide / Q000523:psychology; D016896:Treatment Outcome
D018759:Adrenergic Uptake Inhibitors; D000697:Central Nervous System Stimulants; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride